229 related articles for article (PubMed ID: 10435390)
1. Selective attenuation of the antinociceptive effects of mu opioids by the putative dopamine D3 agonist 7-OH-DPAT.
Cook CD; Rodefer JS; Picker MJ
Psychopharmacology (Berl); 1999 Jun; 144(3):239-47. PubMed ID: 10435390
[TBL] [Abstract][Full Text] [Related]
2. Modulatory effects of dopamine D3/2 agonists on kappa opioid-induced antinociception and diuresis in the rat.
Cook CD; Barrett AC; Syvanthong C; Picker MJ
Psychopharmacology (Berl); 2000 Sep; 152(1):14-23. PubMed ID: 11041311
[TBL] [Abstract][Full Text] [Related]
3. The dopamine D3/2 agonist 7-OH-DPAT attenuates the development of morphine tolerance but not physical dependence in rats.
Cook CD; Barrett AC; Syvanthong C; Picker MJ
Psychopharmacology (Berl); 2000 Sep; 152(1):93-104. PubMed ID: 11041321
[TBL] [Abstract][Full Text] [Related]
4. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour.
Koshikawa N; Kitamura M; Kobayashi M; Cools AR
Eur J Pharmacol; 1996 Jul; 308(3):235-41. PubMed ID: 8858293
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic activity and the discriminative stimulus effects of mu opioids in pigeons: importance of training dose and attenuation by the D3 agonist (+/-)-7-OH-DPAT.
Cook CD; Picker MJ
Psychopharmacology (Berl); 1998 Mar; 136(1):59-69. PubMed ID: 9537683
[TBL] [Abstract][Full Text] [Related]
6. D2 and D1 dopaminergic activity of 7-OH-DPAT.
Sethy VH; Ellerbrock BR; Fici GJ; Wu H
Brain Res; 1996 Sep; 733(1):41-5. PubMed ID: 8891246
[TBL] [Abstract][Full Text] [Related]
7. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats.
Kurashima M; Yamada K; Nagashima M; Shirakawa K; Furukawa T
Pharmacol Biochem Behav; 1995 Nov; 52(3):503-8. PubMed ID: 8545466
[TBL] [Abstract][Full Text] [Related]
8. Effects of dopaminergic agents on antinociception in formalin test.
Zarrindast MR; Nassiri-Rad S; Pazouki M
Gen Pharmacol; 1999 Apr; 32(4):517-22. PubMed ID: 10323495
[TBL] [Abstract][Full Text] [Related]
9. Supraspinal D2 receptor involved in antinociception induced by l-tetrahydropalmatine.
Hu JY; Jin GZ
Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):715-9. PubMed ID: 10678104
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: II. Effects of dopamine D2/3 agonists.
Cook CD; Beardsley PM
Behav Pharmacol; 2004 Feb; 15(1):75-83. PubMed ID: 15075629
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of putative dopamine D3 receptor agonists, 7-OH-DPAT and quinpirole, on prolactin secretion in rats.
Kurashima M; Domae M; Inoue T; Nagashima M; Yamada K; Shirakawa K; Furukawa T
Pharmacol Biochem Behav; 1996 Feb; 53(2):379-83. PubMed ID: 8808147
[TBL] [Abstract][Full Text] [Related]
12. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine.
Depoortere R; Perrault G; Sanger DJ
Psychopharmacology (Berl); 1996 Apr; 124(3):231-40. PubMed ID: 8740044
[TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; jaw movements.
Koshikawa N; Miwa Y; Adachi K; Kobayashi M; Cools AR
Eur J Pharmacol; 1996 Jul; 308(3):227-34. PubMed ID: 8858292
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus effects of putative D3 dopamine receptor agonists in rats.
Katz JL; Alling KL
Behav Pharmacol; 2000 Sep; 11(6):483-93. PubMed ID: 11103914
[TBL] [Abstract][Full Text] [Related]
15. Decreased locomotor activity after microinjection of dopamine D2/D3 receptor agonists and antagonists into lobule 9/10 of the cerebellum: a D3 receptor mediated effect?
Boulay D; Depoortere R; Perrault G; Sanger DJ
Prog Neuropsychopharmacol Biol Psychiatry; 2000 Jan; 24(1):39-49. PubMed ID: 10659982
[TBL] [Abstract][Full Text] [Related]
16. Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors.
Starr MS; Starr BS
Eur J Pharmacol; 1995 Apr; 277(2-3):151-8. PubMed ID: 7493603
[TBL] [Abstract][Full Text] [Related]
17. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors.
Dall'Olio R; Gaggi R; Voltattorni M; Tanda O; Gandolfi O
Behav Pharmacol; 2002 Dec; 13(8):633-8. PubMed ID: 12478213
[TBL] [Abstract][Full Text] [Related]
18. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
[TBL] [Abstract][Full Text] [Related]
19. 5-hydroxytryptamine (HT)1A receptors and the tail-flick response. II. High efficacy 5-HT1A agonists attenuate morphine-induced antinociception in mice in a competitive-like manner.
Millan MJ; Colpaert FC
J Pharmacol Exp Ther; 1991 Mar; 256(3):983-92. PubMed ID: 1672380
[TBL] [Abstract][Full Text] [Related]
20. Analysis of D2 and D3 receptor-selective ligands in rats trained to discriminate cocaine from saline.
Garner KJ; Baker LE
Pharmacol Biochem Behav; 1999 Oct; 64(2):373-8. PubMed ID: 10515316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
